October 23, 2025
As one of the nation’s leading GLP toxicology partners, Envol Biomedical is proud to join the toxicology community at this year’s American College of Toxicology (ACT) Annual Meeting, taking place in Phoenix, Arizona, November 16–19. ACT represents the premier venue for scientific exchange among toxicologists, study directors, and regulatory professionals — and for Envol, it’s the ideal stage to showcase a year defined by growth, investment, and innovation.
A Year of Expansion and Excellence
In 2025, Envol has continued to evolve its capabilities and leadership team to meet the growing needs of drug developers worldwide. Key milestones include:
- Expansion of our toxicology leadership, with a new Director of Toxicology and additional Study Directors to further strengthen scientific oversight and elevate GLP standards.
- Enhancement of our surgical, ocular, and respiratory model programs, led by an experienced MD neurosurgeon and supported through our ongoing collaboration with Endpoint Preclinical. These efforts extend across nasal and respiratory safety studies, as well as metabolic disease models designed to better replicate real-world therapeutic challenges.
- Growth of our veterinary medicine team, ensuring the highest standard of care across every study.
- Investment in advanced animal model development, supporting complex in vivo studies across a wide range of therapeutic areas — from CNS to ocular and metabolic disease research.
- Implementation of AI-enabled data systems, integrating laboratory information management with advanced analytics for faster, smarter reporting.
- Completion of a full Quality Management System—a major step toward offering a complete suite of GLP-compliant studies beginning in 2026.
- Investment in infrastructure and people, reinforcing Envol’s reputation for responsiveness, technical rigor, and long-term partnership value.
These enhancements build on what Envol’s clients value most: consistent quality, rapid execution, and a team deeply committed to scientific integrity.
Leading the Conversation: Three Exhibitor-Hosted Sessions
Envol will host three exclusive Exhibitor-Hosted Programs during the meeting, each focused on advancing dialogue in critical areas of nonclinical research:
- Novel Approaches in Central Nervous System Biology – Exploring next-generation methods for sample collection and delivery within CNS models.
- The Future of Primate Supply – Addressing sustainability, ethics, and the realities of U.S.-based breeding and colony management.
- Regulatory Change and Its Impact on Drug Development – Featuring insights from Tim McGovern, former FDA official, alongside members of NVA, discussing the evolving regulatory landscape and its implications for toxicology.
(Full session details will be available at the Envol booth during ACT.)
A Commitment to Ethical Research and Sustainable Primate Supply
As the largest private primate research center in the continental United States, Envol remains committed to the responsible, purpose-bred supply of non-human primates. This initiative supports a sustainable and ethically grounded foundation for the next generation of preclinical studies — an area where Envol continues to lead the conversation nationally.
Visit Us in Phoenix
Meet Envol’s leadership and scientific team — including Jake McDonald, PhD, Daniela Schwotzer, PhD, Rainer Espinosa, PhD, Matt Beck, and Yoel Chavez, MD — at our booth throughout the conference. Whether you’re an existing collaborator or exploring new partnerships, we welcome you to learn how Envol is advancing the science of safety through technology, expertise, and care.
And for those attending ACT, keep an ear out for details on Envol’s invite-only cocktail reception, co-hosted with our partners — a relaxed opportunity to connect with industry peers after hours.
See You at ACT 2025
As a proud ACT sponsor, Envol Biomedical looks forward to reconnecting with colleagues, sharing new insights, and continuing our mission to deliver flexible, intelligent, and ethically driven toxicology solutions that move great science forward.